CRISPR

CRISPR5-mafbb

ID

ZDB-CRISPR-230131-10

Name

CRISPR5-mafbb

Previous Names

None

Target

mafbb (1)

Sequence

5' - GGCGAGCCTGGCGACGCAGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The first two "G"s were added.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
hkz56	mafbb
uq47bh	mafbb

Expression

Gene expression in Wild Types + CRISPR5-mafbb

No data available

Phenotype

Phenotype resulting from CRISPR5-mafbb

No data available

Phenotype of all Fish created by or utilizing CRISPR5-mafbb

Phenotype	Fish	Conditions	Figures
optic tectum microglial cell gpr34a expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 4 from Lou et al., 2022
brain microglial cell p2rx7 expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 4 from Lou et al., 2022
brain microglial cell p2ry11 expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 4 from Lou et al., 2022
optic tectum microglial cell decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 4 from Lou et al., 2022
brain microglial cell p2ry12 expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 4 from Lou et al., 2022
brain microglial cell gpr34a expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 4 from Lou et al., 2022
microglial cell EGFP expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 1 from Lou et al., 2022
microglial cell DsRedx expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg	standard conditions	Fig. 1 from Lou et al., 2022
brain macrophage DsRedx expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg; tsu11Tg/tsu11Tg	standard conditions	Fig. 2 from Lou et al., 2022
brain microglial cell EGFP expression decreased amount, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg; tsu11Tg/tsu11Tg	standard conditions	Fig. 2 from Lou et al., 2022
facial lymphatic network lymphatic vascular process in circulatory system decreased process quality, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nim5Tg; y7Tg	standard conditions	Fig. 3 from Arnold et al., 2022
facial lymphatic network lymphatic vascular process in circulatory system decreased process quality, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg	standard conditions	Fig. 2 from Arnold et al., 2022
facial lymphatic network lymph vasculature decreased thickness, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg	standard conditions	Fig. 2 from Arnold et al., 2022
facial lymphatic network lymph vasculature malformed, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg	standard conditions	Fig. 2 from Arnold et al., 2022
facial lymphatic network lymph vasculature decreased volume, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg	standard conditions	Fig. 2 from Arnold et al., 2022
axial lymph vessel has fewer parts of type facial lymphatic network endothelial cell, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg; y7Tg	standard conditions	Fig. 1 from Arnold et al., 2022
facial lymphatic network has fewer parts of type facial lymphatic network endothelial cell, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg; y7Tg	standard conditions	Fig. 1 from Arnold et al., 2022
intersegmental lymph vessel has fewer parts of type intersegmental lymph vessel endothelial cell, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg; y7Tg	standard conditions	Fig. 1 from Arnold et al., 2022
facial lymphatic network malformed, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; nz101Tg; y7Tg	standard conditions	Fig. 1 from Arnold et al., 2022
facial lymphatic network lymphatic endothelial cell migration decreased process quality, abnormal	mafba^uq4bh/uq4bh; mafbb^{uq47bh/uq47bh}; uu1kkTg	standard conditions	Fig. 4 from Arnold et al., 2022
spinal cord macrophage EGFP expression increased amount, abnormal	mafbb^hkz56/hkz56; c264Tg/c264Tg; hkz015tTg/hkz015tTg; szy102Tg/szy102Tg	chemical treatment by environment: metronidazole	Fig. 3 from Lou et al., 2022
spinal cord behavioral response to wounding increased process quality, abnormal	mafbb^hkz56/hkz56; c264Tg/c264Tg; hkz015tTg/hkz015tTg; szy102Tg/szy102Tg	chemical treatment by environment: metronidazole	Fig. 3 from Lou et al., 2022
optic tectum macrophage DsRedx expression increased amount, abnormal	mafbb^hkz56/hkz56; hkz013tTg/hkz013tTg; hkz015tTg/hkz015tTg	chemical treatment by injection: lysophosphatidylserine 18:1	Fig. 5 from Lou et al., 2022
optic tectum macrophage chemotaxis decreased process quality, abnormal	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz013tTg/hkz013tTg; hkz015tTg/hkz015tTg	chemical treatment by injection: lysophosphatidylserine 18:1	Fig. 5 from Lou et al., 2022
optic tectum macrophage DsRedx expression amount, ameliorated	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz013tTg/hkz013tTg; hkz015tTg/hkz015tTg	chemical treatment by injection: lysophosphatidylserine 18:1	Fig. 5 from Lou et al., 2022
microglial cell EGFP expression amount, ameliorated	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg; hkz042Tg/hkz042Tg	standard conditions	Fig. 1 from Lou et al., 2022
microglial cell EGFP expression amount, ameliorated	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg; hkz043Tg/hkz043Tg	standard conditions	Fig. 1 from Lou et al., 2022
optic tectum microglial cell decreased amount, ameliorated	mafba^uq4bh/uq4bh; mafbb^hkz56/hkz56; hkz015tTg/hkz015tTg; hkz044Tg/hkz044Tg	standard conditions	Fig. 4 from Lou et al., 2022

Citations